Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Recent News View All News
Recent Events View IR Calendar
Morgan Stanley 23rd Annual Global Healthcare Conference
Email Alerts
Sign up for email alerts for Press Releases & SEC Filings